Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 15/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.68 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.68 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.68 |
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541048 | 0.98 | LMNA (0.68) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL31635262 | 0.91 | L3MBTL1 (0.69) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL31635250 | 0.89 | PTPRC (0.65) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL5346635 | 0.88 | ALDH1A1 (0.74) | KDM4ELMNAPTPRCPTPN13 | |
| SCHEMBL137348 | 0.88 | HDAC4 (0.85) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL6665592 | 0.88 | HDAC4 (0.85) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL1065393 | 0.88 | HDAC4 (0.85) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL6669511 | 0.88 | HDAC4 (0.85) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL17457478 | 0.87 | MAPT (0.82) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL17457479 | 0.87 | MAPT (0.82) | HDAC4HDAC1HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102197-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260125343-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026102197-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125343-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250120928-A1 | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES, AND NANOPARTICLES, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-04-17 | — | — | US | disclosed |
| CN-115784986-A | HDAC6 inhibitor and preparation method and application thereof | 中国海洋大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-115266868-A | Specific electrochemical sensor based on metal oxide and construction method and application thereof | 苏州大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-113214113-B | Preparation method of aniline para-trifluoromethylated derivative | 苏州大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-113214113-A | Preparation method of aniline para-trifluoromethylated derivative | 苏州大学 | 2021-08-06 | — | — | CN | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| WO-2006127321-A2 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1663953-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC11 8/4885 |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | HDAC4 5/4885HDAC1 1/4885HDAC11 7/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC4 4/4885HDAC1 3/4885HDAC11 6/4885 |
| US-20250120928-A1 | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES, AND NANOPARTICLES, AND METHODS OF USE THEREOF | CD44, HDAC6, HDAC3 | HDAC4 6/4885HDAC1 4/4885HDAC11 8/4885 |
| US-20260125343-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | HDAC8, HDAC7, SUB1 | HDAC4 7/4885HDAC1 4/4885HDAC11 8/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC4 27/4885HDAC1 5/4885HDAC11 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.